Literature DB >> 3358573

Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986).

D M Knowles1, G A Chamulak, M Subar, J S Burke, M Dugan, J Wernz, C Slywotzky, G Pelicci, R Dalla-Favera, B Raphael.   

Abstract

We identified 105 patients with lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS) at the New York University Medical Center from 1981 through 1986: 89 had non-Hodgkin lymphoma; 13, Hodgkin disease; and 3, chronic lymphocytic leukemia. Immunophenotypic and antigen receptor gene rearrangement analysis showed the B-cell origin of all non-Hodgkin lymphomas studied and the clonal suppressor-cytotoxic T-cell subset origin of the chronic lymphocytic leukemias. We classified 69% of the non-Hodgkin lymphomas as high grade (small, noncleaved and large cell, immunoblastic-plasmacytoid) and 31% as intermediate grade (diffuse large cell). Each histopathologic category was correlated with distinct clinical features, including a statistically significant difference in median survival. Patients with Hodgkin disease had an atypical, aggressive clinical course, whereas patients with T-cell chronic lymphocytic leukemia had an indolent clinical course. These studies show the clinical, morphologic, and immunophenotypic spectrum of AIDS-associated lymphoid neoplasia, that the natural history of Hodgkin disease is altered in patients with AIDS, and support the Centers For Disease Control's recent revision in diagnostic criteria for AIDS to include intermediate-grade diffuse, aggressive non-Hodgkin lymphomas occurring in patients seropositive for human immunodeficiency virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358573     DOI: 10.7326/0003-4819-108-5-744

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  38 in total

1.  TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues.

Authors:  M Teitell; M A Damore; G G Sulur; D E Turner; M H Stern; J W Said; C T Denny; R Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

Review 2.  HIV-associated lymphomas.

Authors:  D J Straus
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

3.  Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis.

Authors:  Elaine J Schattner; Steven M Friedman; Paolo Casali
Journal:  Autoimmunity       Date:  2002-07       Impact factor: 2.815

4.  Granulocytic sarcoma and HIV.

Authors:  John R Krause; Ibrahim Aburiziq
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-10

5.  Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association.

Authors:  Wen Fan; Darya Bubman; Amy Chadburn; William J Harrington; Ethel Cesarman; Daniel M Knowles
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 6.  Paediatric oncology in developing countries.

Authors:  G Prindull
Journal:  Eur J Pediatr       Date:  1991-08       Impact factor: 3.183

7.  Mastoiditis, lymphoma, and AIDS.

Authors:  T Lowry; L Raja; A Verghese
Journal:  West J Med       Date:  1998-09

8.  Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases.

Authors:  D Schürmann; D Dienemann; G Jautzke; J Cervos-Navarro; A Langford; H Stein; H D Pohle; B Ruf
Journal:  Klin Wochenschr       Date:  1991-10-02

9.  Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas.

Authors:  Xianfeng F Zhao; Merry Y Zhao; Ling Chai; Debra Kukuruga; Ming Tan; Sanford A Stass
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

10.  AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization.

Authors:  S J Hamilton-Dutoit; G Pallesen; M B Franzmann; J Karkov; F Black; P Skinhøj; C Pedersen
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.